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ABSTRACT
Osseointegration of Temporary Anchorage Devices Using Recombinant
Human Bone Morphogenetic Protein-2
Erin E. Cruz

Over the past 5 years, the use of titanium implants as temporary anchorage
devices (TADs) has become an important tool in clinical orthodontic practices. The
use of TADs have provided orthodontists a way of moving teeth against fixed objects
rather than against the surrounding teeth, which tend to counteract desired motion. At
present, viable attachment of TADs involves direct insertion through gingival tissue
and piercing of the bone. Surface modifications such as sandblasted and acid-etched
treatment or bone morphogenetic protein surface treatment, however, can be applied
to the TADs to promote enhanced osseointegration, thereby allowing the TADs to
serve as stable anchors while avoiding bone puncture. In this study, a comparison
was made between sandblasted/acid-etched TADs and sandblasted/acidetched/recombinant human bone morphogenetic protein-2 (rhBMP-2) treated TADs
to determine whether rhBMP-2 promotes enhanced osseointegration. A total of 10
rats (4 controls and 6 treated with rhBMP-2) were used in the study, with 1 TAD
placed on the skull of each rat. At the end of 6 weeks, the animals were euthanized
by carbon dioxide asphyxiation, and bone blocks, each containing a TAD, were
prepared for histological examination and biomechanical characterization. The
results of this study showed that TADs treated with rhBMP-2 had greater bone
formation at the bone-implant interface and an increase in total implant stability.

Keywords: recombinant human bone morphogenetic protein-2 (rhBMP-2),
osseointegration, temporary anchorage device, sandblasted and acid etched, titanium

iv

ACKNOWLEDGMENTS

I would like to take this time to thank everyone who has provided me with guidance
and support throughout my thesis project.
I would especially like to thank Dr. John DeVincenzo (or Dr. D as most of us knew
him), for his support and assistance throughout my thesis project. His
recommendations and suggestions throughout this process were invaluable. Dr. D
was very passionate about research and was continually trying to find ways to
improve on existing technologies, such as temporary anchorage devices, in order to
improve the quality of life for his orthodontic patients. Special thanks to Dr. D for
standing by my side during every rat surgery and providing me with the skills I need
to become a better researcher. I know he would be very proud if he was still here
today. I dedicate my thesis to Dr. John DeVincenzo. He will truly be missed.
I would also like to give a big thanks to my thesis advisor, Dr. Lanny V. Griffin, for
his direction, assistance, and guidance. I am grateful for everything he has taught me
throughout my undergrad and graduate studies at Cal Poly, San Luis Obispo. Dr.
Griffin’s patience, encouragement, and support throughout this process is the reason I
was able to successfully complete my thesis project.
Special thanks to my twin sister, Eden Cruz, who has been there for me from day one
of my thesis project. She has a passion for learning and a drive to succeed. I could not
have finished my thesis or made it through Cal Poly without her.
Lastly, I would like to thank my parents, Edna and Jaime Cruz, for their continued
support and encouragement through my studies at Cal Poly, San Luis Obispo. My
mom and dad have always supported me in everything and I cannot thank them
enough for all they have done for me.

v

TABLE OF CONTENTS
Page
LIST OF TABLES ……………………………………………………………..
LIST OF FIGURES ……………………………………………………………..

viii
ix

CHAPTER
1.

LITERATURE REVIEW ………………………………………………..

1

2.

RESEARCH & SPECIFIC AIMS ………………………………………..
Objective ………………………………………………………….
Specific Aim ……………………………………………………...
Hypothesis ………………………………………………………..

8
8
8
9

3.

MATERIALS & METHODS …………………………………………….
Subjects …………………………………………………………..
Guidelines ………………………………………………..
Rationale for Species and Numbers ……………………..
Implant Preparation ………………………………………………
Surgical Procedures ……………………………………………...
General …...………………………………………………
Pre-Operative …….………………………………………
Operative …………………………………………………
Post-Operative ……………………………………………
Historical Examination …………………………………………..
Biomechanical Testing …………………………………………
General …………………………………………………
Experimental Model ………….………………………….
Test Setup for Biomechanical Testing ………………….

10
10
10
10
11
12
12
13
16
18
19
19
19
19
20

4.

RESULTS ……………………………………………………………….
Histological Examination Results Summary ……………………
Biomechanical Testing …………………………………………...
Results Summary ………………………………………..
Mean Failure Load and Standard Deviation ……………

22
22
23
23
24

5.

DISCUSSION OF RESULTS…………………………………………...
Bone Coverage on TAD ………………………………………..
TAD Stability ………………….………………………………..

26
26
28

6.

CONCLUSIONS ………………………………………………………..

31

REFERENCES …………………………………………………………………

32

vi

APPENDICES
A.
Rat Surgery Details from Lab Notebook ……….……………….
B.
Preliminary Experiment Using One Rat ………………………...
C.
Surgery Checklist ………………………………………………
D.
Preliminary Experiment Using INFUSE® Bone
Graft Sample Kit ………………………………………………...
E.
Anesthetics/Analgesics …………………………………………
Bottle Concentrations (mg/mL) …………………………
Dosage (mg/kg of body weight) ………………………...
F.
Butyl Cyanoacrylate and the Effect of UV Light
on Curing Time ….......................................................................
G.
Bone Coverage Raw Data ………………………………………..
H.
Biomechanical Testing Failure Load Graph …………………….

vii

35
40
48
51
55
55
55
57
61
64

LIST OF TABLES
Table
Page
4-1

Percent Bone Coverage on TAD ……………………………………….

22

4-2

Failure Load Data for Each Rat …………………………………………

24

A-1

Rat Surgery Details …………………………………………………….

35

E-1

Number of mL Administered of Each Drug Based on Weight ………...

55

F-1

Vetbond Butyl Cyanoacrylate Curing Time …………………………..

58

G-1

TAD Bone Coverage Photographs for Each Rat ………………………

61

viii

LIST OF FIGURES
Figure
Page
1-1

Picture of Onplant ………………………………………………………… 3

3-1

Wetting 1 cm x 1 cm Collagen Sponge with 0.09cc of Saline …………… 12

3-2

Wetted Collagen Sponge Placed on Top of Control TAD ……………….. 12

3-3

Experimental Model for Biomechanical Testing ………………………… 20

3-4

Biomechanical Testing Setup …………………………………………….

20

3-5

Applying Load to Implant ………………………………………………

21

4-1

Average Percent Bone Coverage & Standard Deviation ………………… 23

4-2

Mean Failure Load & Standard Deviation ……………………………….

5-1

Percent Bone Coverage Summary for Control TAD …………………….. 27

5-2

Percent Bone Coverage Summary for an rhBMP-2 Treated TAD ………. 28

5-3

Failure Load Summary for rhBMP-2 Treated TAD ……………………..

29

5-4

Failure Load Summary for Control TAD …………………………….....

30

D-1

Collagen Sponge Dimensions …………………………………..............

53

F-1

Curing Time Using Cow Bone without UV Light ………………………. 58

F-2

Curing Time Using NY Steak without UV Light ……………………….

59

F-3

Curing Time Using Cow Bone with UV Light …………………………

59

F-4

Curing Time Using NY Steak with UV Light …………………………… 60

H-1

Failure Load for Rat #9 ………………………………………………….. 64

H-2

Failure Load for Rat #10 ………………………………………………… 65

H-3

Failure Load for Rat #11 ………………………………………………… 65

ix

25

H-4

Failure Load for Rat #21 ………………………………………………..

65

H-5

Failure Load for Rat #22 ……………………………………………….

66

H-6

Failure Load for Rat #23 ………………………………………………

66

H-7

Failure Load for Rat #24 ……………………………………………….

67

H-8

Failure Load for Rat #27 ……………………………………………….

67

x

1. LITERATURE REVIEW
For more than 40 years, titanium has been widely used as a biocompatible implant
material for dental applications. In general and prosthetic dentistry, titanium implants
today have become a regular and customary alternative to one or more missing teeth.
Orthodontics, however, has been slow in using this important tool as a temporary anchor.
It has only been in the last 5 years that an explosion of temporary anchorage devices
(TADs) has appeared in clinical orthodontic practices.

During orthodontic treatment, TADs control tooth movement by preventing
unwanted or allowing desired dental movement [1]. In orthodontics, the difficulty that
usually arises when moving teeth is that the surrounding teeth tend to counteract the
desired motion. This is consistent with Newton’s third law, which states that for every
action, there is an equal and opposite reaction. However, instead of using molars as
anchors, which may facilitate movement of the teeth (action / reaction forces) as defined
by Newton’s third law, the use of TADs allows teeth to be moved against fixed objects
rather than against the surrounding teeth. Therefore, TADs provide orthodontists and
patients with appealing treatment alternatives to restorative and surgical procedures.

Although TADs show great potential in orthodontic practice, they also introduce
possible serious risks to the anatomical structures of the maxillary and mandibular bones.
If there is inadequate amount of bone available at the implant site or insufficient space to
insert TADs that are 5 to 12 mm in length and 1.3 to 2 mm in diameter, then the roots of
the adjacent teeth, soft tissue, sinus and nasal cavities, and neurovascular bundles could
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be damaged [2, 3]. At present, viable attachment of TADs involves direct insertion
through the gingival tissue and piercing of the bone. Unfortunately, bone puncture may
induce bone infections, such as localized or systemic osteomyelitis. In addition, when
considering the roots of the teeth, a bone piercing TAD would be limited in terms of
insertion site. With a bone piercing TAD, the TAD would have to be placed between the
roots in order to avoid injury to the roots or other anatomical structures nearby. With this
in mind, would it be possible to get the undersurface of a TAD to adhere to bone and thus
avoid the undesirable side effects associated with bone piercing?

In 1995, Block and Hoffman developed a disc-like structure called an “onplant,”
which required less bone depth compared to the usual endosseous (contained within
bone) implants. The onplant is a hydroxyapatite-coated titanium alloy disk that is 10 mm
in diameter and 2 mm high (refer to Fig. 1) and placed on the palatal bone to provide
anchorage for orthodontic tooth movement [3]. Through experimentation, Block and
Hoffman found that the onplant, after subjected to orthodontic forces, provided total
anchorage for tooth movement without reciprocal movement of the onplant [3, 4]. In
addition, the onplant prevented anterior dental retraction by providing maximum
anchorage to molars [3, 4]. However, a disadvantage of the onplant is the complications
that occur with the removal process. During the removal of the onplant, a large portion
of soft tissue must be re-exposed, which could be uncomfortable for the patient.
Although the onplant takes bone height into account and avoids the risks involved with
bone perforation, the removal technique introduces invasive procedures. Would it be
possible to avoid piercing the bone and develop a removal technique that is less-invasive?
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Surface TADs could provide a way to minimize the discomfort associated with the
removal process while avoiding puncture of the bone. However, surface TADs introduce
limitations as well. Compared to longer and wider implants, surface TADs make it more
difficult to achieve mechanical retention. Knowing this, how could the bone-to-TAD
interface be strengthened in order to attain the mechanical retention desired?

Figure 1-1 – Picture of an Onplant
Taken from The Role of Implants in Orthodontic by S.F.H. Ismail and A.S. Johal

Per Ingvar Branemark first coined the term osseointegration when a titanium
cylinder used in one of his experiments had integrated tightly into rabbit bone. More
specifically, osseointegration is defined as the direct structural and functional connection
between living bone and the surface of an implant. Bone-compatible materials such as
titanium, titanium alloys, and hydroxyapatite, have been shown to achieve
osseointegration [4]. Presently, osseointegrated implants are used to treat both
completely edentulous (being without teeth) and partially edentulous ridges. In addition,
osseointegration makes it possible to increase orthodontic anchorage because an implant
directly integrated into bone should not move in response to orthodontic loads [4].
Therefore, through osseointegration, a TAD made of titanium could serve as a stable
anchor.
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For this study, titanium is chosen as the dental implant material because it has
excellent biocompatibility, is strong and lightweight, and is highly resistant to corrosion,
stress, and fracture [5, 6, 7, 8]. Titanium has been used for both endosseous and
subperiosteal implants for many years. In addition, titanium easily passivates to form a
protective oxide layer, which allows the apposition of proteins and tissue to the metal
surface [7]. Thus, titanium itself promotes osseointegration because direct contact occurs
between the bone and the implant surface [7, 9]. Although other materials, such as gold
and platinum, have shown to be corrosion resistant, their low tensile strength makes
titanium a better choice of implant material. Furthermore, stainless steel has also been
used in orthodontic practice because of its resistance to corrosion and its high strength.
Its high corrosion resistance is due to its low carbon and sulfur content and its high
chromium and nickel content. Unfortunately, nickel is not a biocompatible material and
has shown to cause allergic reactions [5]. On the other hand, titanium is well tolerated by
the human body. Therefore, titanium’s physical and mechanical properties, along with its
ability to integrate into bone, make it an advantageous implant material.

According to previous studies, the surface of an implant has been a determining
factor for successful osseointegration (direct bond between living bone and the surface of
an implant), and in particular, microrough titanium surfaces have facilitated enhanced
bone formation and implant stability [9, 10, 11, 12, 13]. The combination of a
sandblasted and acid-etched surface has improved bone apposition [9, 10, 12] and
resulted in higher torque values during biomechanical testing [10, 11, 12]. What if,
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however, it was possible to increase osseointegration even more? This could lead to
enhanced implant coverage by bone as well as an increase in adhesion strength at the
bone-to-implant interface. Therefore, if appropriate surface modifications can be applied
to the TADs to promote enhanced osseointegration, the TADs could serve as stable
anchors while avoiding puncture of the bone. With enhanced osseointegration, the TADs
could develop higher levels of mechanical resistance and stability.

One type of surface modification involves the use of bone morphogenetic protein
(BMP). BMPs belong to a family of growth factors and are known for their pivotal role in
cartilage and bone formation [14, 15, 16, 17, 18]. For decades, BMPs have been studied
because of their ability to heal bone while reducing or eliminating the need to harvest
bone from other parts of the body. So far, a total of 20 BMPs have been discovered, eight
(BMP-2 through BMP-9) of which are members of the transforming growth factor-ß
(TGF-ß) superfamily of proteins. Of these eight, BMP-2 and BMP-7 have gained the
most attention in regards to therapeutic procedures to treat a variety of skeletal conditions
and defects. BMP-2 and BMP-7 have demonstrated the greatest osteogenic capacity by
influencing the differentiation of mesenchymal cells to chondroblasts and osteoblasts
[16]. Experimental studies have shown the importance of BMP-2 and BMP-7 in bone
development and the development of a variety of tissues outside of bone [14, 17].

By understanding the important role that BMP plays in cell growth and
differentiation, scientists have been able to create a genetically engineered version of this
naturally occurring protein called recombinant human bone morphogenetic protein
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(rhBMP). More importantly, a large number of preclinical studies have verified the
ability of rhBMPs to initiate bone growth [16, 17, 18, 19, 20]. In particular, rhBMP-2 has
been studied more than any other BMP and has received Food and Drug Administration
(FDA) approval for human clinical uses, such as oral, spinal, and tibial surgeries. The
local application of rhBMP-2, in addition to a variety of carriers such as a collagen
sponge, has demonstrated the ability to regenerate skull and mandibular defects [15, 17],
enhance periodontal new bone formation [15, 16], improve spinal fusion [15, 16, 18, 19,
21], treat a variety of bone-related conditions such as delayed union and non-union [18],
and promote fracture repair [15, 18, 19].

For this present study, rhBMP-2 is chosen because of its effectiveness in
stimulating bone growth in a variety of applications. Specifically, INFUSE® Bone Graft
(Medtronic Sofamor Danek, Memphis, TN), which consists of rhBMP-2 in combination
with an absorbable collagen sponge (ACS), is used. Medtronic INFUSE® Bone Graft has
helped in the spine by promoting the fusion of vertebral bodies to alleviate back pain. It
has also helped to heal broken bones for tibial fractures, and been used for oral and
maxillofacial bone grafting procedures, such as sinus augmentation and localized alveolar
ridge augmentation. Even though studies have validated the effectiveness of the rhBMP2/ACS in stimulating new bone growth, it is still important to participate in further
studies which will expand knowledge of its use and application.

For rhBMP-2 to enhance osseointegration, the implant must be stabilized.
Without implant stability, there is a risk of microfractures at the implant-bone interface,
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which could decrease the likelihood of osseointegration. Therefore, it is important for
TAD stability to exist before and until osseointegration can be obtained. When a simple
screw TAD is threaded into bone, mechanical resistance can serve as the necessary
stabilizer until osseointegration occurs. Mechanical resistance and stability is achieved
because when a force is applied to a body (i.e. tooth) to the left and produces a
counterclockwise moment about a center of resistance (i.e. screw TAD), an opposite
system counteracts with a force to the right and a moment in the clockwise direction [4].
This means that the sum of all forces equals zero, and the sum of all moments about a
point is also zero. Thus, the screw TAD achieves static equilibrium.

However, when the goal is to avoid bone puncture by surface osseointegration,
what means of stabilization can be employed to ensure that the TAD is stabilized until
osseointegration can be achieved? Since the Vietnam War, cyanoacrylate glues have
been used in medical procedures to seal soft tissue wounds. There are a variety of
cyanoacrylates, and each is appropriate for different applications. For instance, methyl
cyanoacrylates have the most rigid polymer matrix and are excellent for metal-bonding
applications. On the other hand, ethyl cyanoacrylates work well on plastics and
elastomeric substrates [22]. Butyl cyanoacrylate, in particular, has been tolerated by
mammalian tissues and used as a surface dressing at oral wounds of both animals and
human beings [23]. In addition, butyl cyanoacrylate has also shown to reduce edema and
cause minimal tissue response. Using cyanoacrylate to adhere TADs to the bone is very
important to the success of this study because achieving TAD stability is essential for
osseointegration to be obtained.

7

2. RESEARCH & SPECIFIC AIMS
2.1

Objective
The goal of this study is to examine the viability of a combination of existent
technologies, which include temporary anchorage devices (TADs),
sandblasted and acid etched surface treatment, bone morphogenetic protein
surface treatment, and cyanoacrylates. In particular, the goal is to evaluate
the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2)
on the ability of TADs to osseointegrate. A comparison will be made
between sandblasted/acid-etched TADs and sandblasted/acid-etched/rhBMP2 treated TADs to determine whether rhBMP-2 promotes enhanced
osseointegration. Specifically, this research will determine the influence of
Medtronic INFUSE® Bone Graft on implant anchorage and increased bone
formation. Finding a way to enhance bone formation and strengthen bone-toTAD contact (increased implant stability) is important because there is a
significant clinical benefit to patients if a new type of TAD that does not
pierce the bone is available. Not only can teeth movement be controlled
without causing movement to the surrounding teeth, but enhanced bone
formation at the implant site can prevent bone puncture and serious side
effects.

2.2

Specific Aim
To investigate the influence of recombinant human bone morphogenetic
protein-2 (rhBMP-2) on the osseointegration of temporary anchorage devices
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(TADs). This will involve qualitatively examining surface topography and
the amount of the TAD surface covered by bone through photographs and
visual inspection. The bone formation on a sandblasted/acid-etched/rhBMP2 treated TAD will be compared with bone formation on a sandblasted/acidetched control specimen. In addition, biomechanical testing will be done
using a micromechanical testing system to determine if the rhBMP-2
treatment on the TAD produces any significant changes in the bond strength
between the TAD and the bone.

2.3

Hypothesis
Sandblasted and acid-etched temporary anchorage devices (TADs) treated
with recombinant human bone morphogenetic protein-2 (rhBMP-2) will
promote better osseointegration than TADs that are only sandblasted and
acid-etched. Specifically, TADs treated with rhBMP-2 on top will show an
increase in bone formation (implant surface covered by bone) and an increase
in total implant stability (adhesion strength at the bone-to-TAD interface).
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3. MATERIALS & METHODS
3.1 Subjects
3.1.1

Guidelines
Ten adult Sprague-Dawley rats (4 controls and 6 treated with the
absorbable collagen sponge/rhBMP-2 mixture) with an average
weight of 450 ± 70 grams were used in this study. The rats were
handled in accordance with National Institutes of Health (NIH)
guidelines for the care and use of laboratory animals (NIH publication
85-23, Rev. 1985) and the surgeries were performed with the
approval of the Animal Care and Use Committee (IACUC) of
California Polytechnic State University, San Luis Obispo. The details
of each rat surgery (i.e. time of injection, start time of surgery, end
time of surgery, etc.) were recorded in a lab notebook. A copy of this
raw data is found in Appendix A.

3.1.2

Rationale for Species and Numbers
The Sprague-Dawley rat was selected as the appropriate species
choice for this study due to its genetic similarity to humans and its
ability to serve as a general model for the study of human health and
disease. Sprague-Dawley rats are widely used for experimental
purposes, and in particular, their calmness and ease of handling make
them the choice of species for this study. Studies similar to this
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current study have shown sound scientific results with the use of
Sprague-Dawley rats.

Using a 1-Sample t-test, 10 rats (4 controls and 6 treated with the
absorbable collagen sponge/rhBMP-2 mixture) were chosen for this
study so that a sufficient amount of data is produced while limiting
the number of rats to be used.

3.2

Implant Preparation
The temporary anchorage devices (TADs) used in this study are manufactured
from commercially pure titanium and are divided into 2 types of treatments:
Type 1 is sandblasted (with grit) and acid-etched (combination of anorganic
acids, HCl/H2SO4 acid bath), and Type 2 is treated with Medtronic INFUSE®
Bone Graft (recombinant human bone morphogenetic protein-2 placed on an
absorbable collagen sponge) in addition to being sandblasted and acid-etched.
For a type 1 treated TAD, a 1 cm x 1 cm absorbable collagen sponge with
0.09cc of saline will be placed on top of the sandblasted and acid-etched
implant to serve as the control. Refer to Figures 3-1 and 3-2 below.
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Figure 3-1 – Wetting 1 cm x 1 cm
Collagen Sponge with 0.09cc of
Saline

Figure 3-2 – Wetted Collagen
Sponge Placed on Top of
Control TAD

For a type 2 treated TAD, a 1 cm x 1 cm absorbable collagen sponge with
0.09 cc of reconstituted rhBMP-2 will be placed on top of the TAD to serve as
the rhBMP-2 treated TAD. The collagen sponge with saline is used so that
the only variable between the type 1 TAD and the type 2 TAD is the
reconstituted rhBMP-2. The collagen sponge must be soaked in the saline or
rhBMP-2 for at least 15 minutes before it is used.

3.3 Surgical Procedures
3.3.1

General
During preliminary experimentation, one rat was used to evaluate the
following: 1) Effectiveness of the anesthesia (Ketamine, Xylazine,
Buprenorphine), 2) Instrumentation needed to perform the surgical
procedure, 3) Pre-operative, operative, and post-operative guidelines,
4) Type and location of incision, 5) Implant contour, adhesion
method, closure of incision site, and 6) Implant size and protruding
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length. Details of this preliminary experiment can be found in
Appendix B. The actual surgical procedures performed for this study
were completed based on the findings from the preliminary
experiments. In addition, a Surgical Checklist which is found in
Appendix C was created to ensure that all materials and instruments
were in the surgical suite at the time of surgery, and that no
procedural steps were missed.

3.3.2

Pre-Operative
The instruments used during the procedure were sterilized by heat
sterilization prior to prep and surgery. The following instruments
were sterilized: a tray for rhBMP-2 procedures, forceps, fine forceps,
ultrafine forceps, scissors, scalpel, butyl cyanoacrylate applicator,
glass slab for butyl, surgical drapes, syringes, gloves, Petri dish with
saline, cotton gauze, and cotton swabs. Once the instruments were
sterilized, they were brought to the surgical suite along with other
materials/equipment such as butyl cyanoacrylate, tupperware for
weighing the rat, isolation mask and cap, sterile gowns, bench covers,
weight boat, and the rat in its cage.

Once all the instruments and equipment were available in the surgical
suite, the assistant prepared the absorbable collagen sponge (ACS) for
use in surgery. In preparation for surgery that used a control TAD,
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0.09cc of saline was placed on a 1cm x 1 cm ACS using a syringe and
sterile tray. Likewise, in preparation for surgery that used an rhBMP2 treated TAD, 0.09cc of reconstituted rhBMP-2 was placed on a 1cm
x 1 cm ACS using a syringe and sterile tray. The collagen sponge was
soaked in the saline (or rhBMP-2) for at least 15 minutes.
Preliminary experiments were done to determine the appropriate size
of ACS and the amount of rhBMP-2 required for each implant, as
well as the best tool for cutting the sponge and the best method for
shaping the sponge during the procedure. Details of these
experiments can be found in Appendix D.

While the ACS soaked in either saline or rhBMP-2, the rat was
weighed to determine the appropriate dosages of Ketamine, Xylazine,
and Buprenorphine to be administered to the rat. The rat was placed
on a bench cover and a mixture of Ketamine and Xylazine (44 mg/kg
body weight of Ketamine, 10 mg/kg body weight of Xylazine) was
used for inducing general anesthesia. This provided approximately 30
minutes of effective anesthesia. A ½ dose was readily available for
surgeries that took longer than expected. The source used to
determine these dosages was Lumb and Jones Veterinary Anesthesia
and Analgesia, 4th Ed. by W. J. Tranquilla. In addition, a dose of
Buprenorphine was administered subcutaneously (0.01 – 0.05 mg/kg
body weight) between the shoulder blades for pain mitigation [24].
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The rat was then placed in a chamber until the anesthesia took effect
and the animal was down. The table in Appendix E shows the
number of mL of each drug that should be administered based on the
rat’s weight. The dosages were recorded in a lab notebook which is
under lock and key at the California Polytechnic State University, San
Luis Obispo surgical suite. The Ketamine/Xylazine and
Buprenorphine mixture works well because emergence from
anesthesia is smoother and has a high factor of safety. Under
anesthesia, the rat did not respond to various audible and tactic
stimuli, and maintained a normal breathing and heart rate. Once the
anesthesia had taken effect and the rat was in Stage 3, it was taken out
of the chamber to undergo prep procedures.

The assistant prepped the rat by shaving the surgical site (rat’s head),
applying depilatory cream to remove excess hair, and disinfecting the
area with Betadine solution using sterile cotton swabs applied in a
circular motion. This process was preformed 3 times (with 3 different
cotton swabs) and the antiseptic was in contact with the skin for a
minimum of 3 minutes before incision. The rat was put back in the
chamber while the surgical area was prepped.

The surgical area was prepped by disinfecting the table to maintain a
clean, uncluttered, and sanitized area. A new bench cover was placed
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on the table and the rat was placed on top of it.

To prep for post-

operative procedures, the assistant also placed a heating pad in the
microwave so that it was ready to heat up once the surgical
procedures were completed. Once the “surgeon” had scrubbed and
put on the sterile gown, he/she put on the sterile gloves and sat down
to begin surgery. The assistant carefully opened the pre-sterile
package containing the sterile surgical drape and the surgeon
removed the drape from the packaging and placed it over the rat to
ensure that aseptic standards were met. With the help of the assistant,
the other sterile packages containing the sterile instruments, butyl
cyanoacrylate/applicator, glass slab, gauze, and cotton swabs were
also opened while the surgeon removed the contents of those sterile
packages and placed them onto the sterile field. The rat was ready to
undergo the surgical procedure.

3.3.3 Operative Procedures
Using the “tips-only” technique, the surgeon made an incision
approximately 1 inch in length along the midline of the head from the
eyes to the ears using firm pressure to guarantee a clean cut in a single
stroke. Once the incision was made, the periosteum was carefully
folded back to expose the bony complex on the surface of the cranium.
Sterile forceps were used to pick up one temporary anchorage device,
contour it to fit the shape of the animal’s skull, and place it on the
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surface of the cranial bone. Preliminary experiments showed that only
one 7mm diameter TAD can be successfully placed on the skull and
covered with the periosteum. The periosteum is too thin to effectively
cover more than one implant. In addition, preliminary experiments
confirmed that a protruding length of 2mm on one side of the TAD is
adequate for biomechanical testing but small enough to prevent the rat
from knocking it off.

The implant was then attached to the bone using the tissue glue, butyl
cyanoacrylate, which took approximately 2 minutes to set. The TAD
was placed on the cranial bone such that its distance from the cranial
surface was as close as possible, allowing for enhanced bone
apposition and likelihood of osseointegration. Butyl cyanoacrylate
was evaluated during preliminary experiments and was shown to be an
effective adhesive. It was also determined through preliminary
experimentation that although the curing time with UV light is less
than the curing time without UV light, the difference is not significant
enough to require the use of UV light for this study. Refer to
Appendix F for details and results of these preliminary experiments.

For both the control and the rhBMP-2 treated TADs, sterile forceps
were used to place the wetted collagen sponge on top of the implant.
The collagen sponge was wet with saline or reconstituted rhBMP-2
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depending if it was a control implant or not. While surgery was in
progress, the animal’s vital signs were continually monitored. Once
the TAD was stable, the periosteum was folded back over the implant.
Sterile forceps were used to hold the sides of the skin at the incision
site together while the incision was closed using butyl cyanoacrylate.
This completed the surgery. The circulating heating pad was then
heated up in the microwave for about 3-4 minutes to heat up to 37
degrees.

3.3.4

Post-Operative
After surgery and the removal of the surgical drape, the rat was given
a subcutaneous injection of Burprenorphine (0.01 – 0.05 mg/kg). The
rat was then moved to a warm area (recovery bin) where it was
monitored during recovery. A heating pad was used to return the
animal’s body temperature back to normal. Upon full recovery from
the anesthesia, the rat was returned to its routine housing; each rat
was caged separately. Buprenorphine was administered 3 times a day
for 2 days as necessary for pain management. The rats were visually
inspected daily post-op for infection, and a surgical record
(procedure, date, anesthesia dose, route of administration) was
maintained.
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3.4

Histological Examination
The rats were euthanized by carbon dioxide asphyxiation and a qualitative
analysis of surface topography and the amount of the TAD surface covered
by bone was conducted through photographs and visual inspection. A
comparison of surface topography and TAD coverage was made between
the sandblasted/acid-etched/rhBMP-2 treated TAD and the control
specimen (sandblasted and acid-etched TAD). The results of the
histological examination are found in Section 4.1 below.

3.5

Biomechanical Testing
3.5.1

General
After qualitative analysis, biomechanical testing was performed
using the In Spec, Instron Corporation, Camden, MA
micromechanical testing system. Load was applied to the upper
part of each temporary anchorage device in the shear direction
with a force at constant speed until the surrounding bone was
destroyed.

3.5.2

Experimental Model
As a proof of experimental concept, the TAD was imbedded onto
a polyurethane 20 lb foam block and attached to the In Spec,
Instron Corporation, Camden, MA micromechanical testing
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system with a 50 N load cell. Five replicate tests were conducted
with an average shear load of 8.9 N ± 1.5 N.

Figure 3-3 – Experimental Model for Biomechanical Testing

3.5.3

Test Setup for Biomechanical Testing

Figure 3-4 – Biomechanical Testing Setup
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Figure 3-5 – Applying Load to Implant
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4.

RESULTS
4.1

Histological Examination Results Summary
Visual inspection of the TADs prior to biomechanical testing showed bone
formation on both the control TADs and the TADs treated with rhBMP-2.
However, TADs treated with rhBMP-2 had a greater amount of bone
coverage (enhanced osseointegration) than the control TADs. For all but
one of the rhBMP-2 treated TADs (exception is Rat # 10), only the
protruding portion of the TAD was visible after 6 weeks of implantation in
the rat’s skull as the top surface of the TAD was almost entirely covered in
new bone. For Rat #10, the TAD site was infected and thus had minimal
to no bone coverage. Table 4-1 below shows the percentage of bone
coverage observed on each TAD for each rat. The raw data (TAD
photographs) can be found in Appendix G.

Rat #
Rat 5
Rat 6
Rat 7
Rat 9
Rat 10
Rat 11
Rat 19
Rat 21
Rat 22
Rat 23
Rat 24
Rat 26
Rat 27

Table 4-1 – Percent Bone Coverage on TAD
Control or rhBMP-2 treated
Percent Bone Coverage
Control, sponge on top
10%
Control, sponge on top
0% – TAD migrated
Control, sponge on top
N/A - rat died after surgery
Sponge on top w/ rhBMP-2
99%
Sponge on top w/ rhBMP-2
0% - TAD site is infected
Sponge on top w/ rhBMP-2
90%
N/A– rat died a few days after
Sponge on top w/ rhBMP-2
surgery
Control, sponge on top
10%
Sponge on top w/ rhBMP-2
99%
Sponge on top w/ rhBMP-2
99%
Control, sponge on top
5%
N/A - Rat died one day after
Sponge on top w/ rhBMP-2
surgery
Sponge on top w/ rhBMP-2
99%
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Based on the data in Table 4-1 above, the average percentage of bone
coverage on a control TAD was 6.25 ± 4.79% while the average
percentage of bone coverage on an rhBMP-2 treated TAD was 97.2 ±
4.02% (Figure 4-1).

Average Percent Bone Coverage & Standard Deviation

Percent Bone Coverage (%)

120
100
80
Control mean + stdev
60
rhBMP-2 mean + stdev
40
20
0
Treatment Type

Figure 4-1 – Avg. Percent Bone Coverage & Stdev

4.2

Biomechanical Testing
4.2.1 Results Summary
The biomechanical testing results showed that TADs treated with
the rhBMP-2 on top have a significantly greater failure load than
the control TADs. The failure load for the rhBMP-2 treated
TADs ranged from 32.02 N – 98.39 N, whereas the failure load
for the control TADs ranged from 0 N – 5 N. The value of 0.96 N
for rat #10 was excluded as the TAD site was found to be infected
and thus inconclusive. See details in Table 4-2 below.
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Rat #
Rat 5
Rat 6
Rat 7
Rat 9
Rat 10
Rat 11
Rat 19
Rat 21
Rat 22
Rat 23
Rat 24
Rat 26
Rat 27

Table 4-2 – Failure Load Data for Each Rat
Control or rhBMP-2 treated?
Failure Load
Data lost but failure load observed on
Control, sponge on top
hand-held device was ≈ 5 N
0 N - No testing performed as TAD
Control, sponge on top
migrated during the 6 weeks
Control, sponge on top
N/A – rat died after surgery
Sponge on top w/ rhBMP-2
88.16 N
Sponge on top w/ rhBMP-2
0.96 N – TAD site is infected
Sponge on top w/ rhBMP-2
32.02 N
Sponge on top w/ rhBMP-2
N/A – rat died after surgery
Control, sponge on top
4.99 N
Sponge on top w/ rhBMP-2
98.39 N
Sponge on top w/ rhBMP-2
92.92 N
Control, sponge on top
2.84 N
Sponge on top w/ rhBMP-2
N/A – rat died one day after surgery
Sponge on top w/ rhBMP-2
68.14 N

4.2.2 Mean Failure Load & Standard Deviation
Based on the data in Table 4-2 above, the mean failure load for
the control TADs is 3.21 N ± 2.37 N while the mean failure load
for the rhBMP-2 treated TADs is 75.93 N ± 27.07 N (Figure 4-2
below).
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Mean Failure Load & Standard Deviation
120

Failure Load (N)

100
80
Control mean + stdev
60
rmBMP-2 mean +stdev
40
20
0
Treatment Type

Figure 4-2 – Mean Failure Load & Standard Deviation
The failure load graphs for each rat/TAD are found in Appendix H.
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5.

DISCUSSION OF RESULTS
5.1

Bone Coverage on TAD
Bone formation was observed on both the control TADs and the TADs
treated with rhBMP-2. Control TADs had a percentage of bone coverage
of 6.25 ± 4.79%. For 3 of the 4 control TADs, bone coverage was present
as a result of its sandblasted and acid-etched surface. As described in the
Literature Review section of this paper, the combination of a sandblasted
and acid-etched surface has been known to improve bone apposition.
Based on the results, this type of microrough titanium surface does in fact
facilitate the formation of new bone.

For 1 of the control TADs, however, no bone coverage was observed as
the implant had migrated sometime during the 6 week implantation period.
The reason for implant migration may be due to one or a combination of
the following: 1) the TAD was knocked loose during the 6 week
implantation period (i.e. the rat knocked it out of place), 2) not enough
butyl cyanoacrylate was used to glue the TAD to the bone during the rat
surgery resulting in an unstable TAD, and 3) not enough butyl
cyanoacrylate was used to adequately seal the surgical incision making it
easier for the rat to knock the TAD out of place. Without TAD stability,
the risk of microfractures at the TAD-bone interface increases which in
turn decreases the likelihood of osseointegration. See Figure 5-1 below
for the percent bone coverage summary for a control TAD.
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Percent Bone Coverage Summary for Control TAD
A nderson-Darling N ormality Test
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7.5
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Figure 5-1 – Percent Bone Coverage Summary for Control TAD

Even further, the TADs which were sandblasted, acid-etched, and treated
with rhBMP-2, showed even more bone coverage (enhanced
osseointegration) than the control TADs. For all but one of the rhBMP-2
treated TADs (exception is Rat # 10), only the protruding portion of the
TAD was visible after 6 weeks of implantation in the rat’s skull as the top
surface of the TAD was almost entirely covered in new bone.
Specifically, the rhBMP-2 treated TADs had a percentage of bone
coverage of 97.2 ± 4.02%. Compared to a control TAD, the percent bone
coverage on an rhBMP-2 treated TAD was significantly greater. This
shows that rhBMP-2 promotes enhanced osseointegration. The
significance of rhBMP-2 on enhancing bone formation was quantified
during biomechanical testing which is discussed in Section 5.2 below. See
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Figure 5-2 below for the percent bone coverage summary for an rhBMP-2
treated TAD.
Percent Bone Coverage Summary for an rhBMP-2 treated TAD
A nderson-D arling N ormality Test
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94
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Figure 5-2 – Percent Bone Coverage for an rhBMP-2 treated TAD

As referenced above, although the TAD in Rat #10 was treated with
rhBMP-2, visual inspection of the TAD prior to biomechanical testing
showed minimal to no bone formation compared to the rest of the rhBMP2 treated TADs. This TAD site was found to be infected, which likely
interfered with bone formation in this area.

5.2

TAD Stability
The biomechanical testing results showed that TADs treated with the
rhBMP-2 on top have a significantly greater failure load than the control
TADs. The failure load for the rhBMP-2 treated TADs ranged from 32.02
N – 98.39 N, whereas the failure load for the control TADs ranged from 0
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N – 5 N. The value of 0.96 N for rat #10 was excluded from the
calculation and analysis for the rhBMP-2 treated TADs as the TAD site
was found to be infected and thus inconclusive. The large range for the
rhBMP-2 treated TADs is largely due to TAD stability (i.e. how well the
butyl cyanoacrylate glues the TAD to the bone prior to osseointegration or
how well the TAD contours to the rat’s skull). The more stable the TAD,
the better chance for enhanced osseointegration. On average, the amount
of force required to pull an rhBMP-2 treated TAD from the bone was
75.93 N ± 27.02 N. See Figure 5-1 below for the failure load summary for
an rhBMP-2 treated TAD. This average does not include the data for Rat
#10.

Failure Load Summary for rhBMP-2 treated TAD
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Figure 5-3 – Failure Load Summary for rhBMP-2 Treated TAD

29

77.791

In contrast, the average amount of force required to pull a control TAD
from the bone was 3.21 N ± 2.37 N. See Figure 5-2 below for the failure
load summary for a control TAD. This average includes the data for Rat
#6, which is 0 N since the TAD migrated sometime during the 6 week
timeframe. If 0 N was removed as a data point based on the assumption
that osseointegration would have occurred had the TAD been stable, then
the average failure load would be 4.23 N ± 1.24 N.

Failure Load Summary for Control TAD
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Figure 5-4 – Failure Load Summary for Control TAD
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8.8269

6.

CONCLUSIONS
Based on the visual inspection and biomechanical testing results, sandblasted and

acid-etched temporary anchorage devices (TADs) treated with recombinant human bone
morphogenetic protein-2 (rhBMP-2) promote better osseointegration than TADs that are
only sandblasted and acid-etched. Specifically, TADs treated with rhBMP-2 showed an
increase in bone formation (avg. of 97.2% TAD surface covered by bone vs. avg. of
6.25% TAD surface covered by bone) and an increase in total TAD stability, or adhesion
strength at the bone-to-TAD interface (avg. of 75.93 N vs. avg. of 3.21 N).

By promoting enhanced osseointegration, rhBMP-2 helps the TADs serve as
stable anchors while avoiding puncture of the bone. In addition, butyl cyanoacrylate
plays a key role in providing TAD stabilization until osseointegration can be achieved.
As evident in the results, TADs which have become loose or migrated early in the
implantation stages will have minimal or no osseointegration. With the use of TADs as
stable anchors, teeth movement can be controlled without causing movement to the
surrounding teeth and with enhanced bone formation at the TAD site, this eliminates the
need for direct insertion through the gingival tissue and into the bone which reduces the
chances of developing bone infections. These characteristics can provide a significant
clinical benefit for orthodontic patients.
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Appendix A
Rat Surgery Details from Lab Notebook
Table A-1 – Rat Surgery Details
Rat #
Date
Sponge Type
5
10/3/2008 Control, sponge
on top

Time
8:00pm

8:08pm
8:09pm
8:39pm
9:51pm

6

10/4/2008

6:20am

11/15/2008

5:30pm

10/3/2008

Control, sponge
on top

9:00pm

9:05pm
9:13pm
9:45pm
10:54pm

7

10/4/2008

6:25am

11/15/2008

5:30pm

10/3/2008

Control, sponge
on top

9:30pm

9:45pm
10:00pm
10:20pm
10:25pm
35

Action
IP injection of 0.22cc Ketamine
and 0.25cc Xylazine
Subcutaneous injection of
0.0495cc Buprenorphine and 15cc
saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0495cc Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.18cc Ketamine
and 0.21cc Xylazine
Subcutaneous injection of 0.04cc
Buprenorphine and 15cc saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.04cc
Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.16cc Ketamine
and 0.18cc Xylazine
Subcutaneous injection of 0.04cc
Buprenorphine and 15cc saline
Additional IP injection of 0.10cc
Ketamine and 0.10cc Xylazine
Additional IP injection of 0.15cc
Ketamine and 0.17cc Xylazine
Additional IP injection of 0.16cc
Ketamine and 0.18cc Xylazine
Apply 0.09cc saline on collagen

Rat #

Date

Sponge Type

Time

Sponge on top
with rhBMP-2

7:13am

10/4/2008
10/8/2008
9

10/4/2008

Action
sponge
10:30pm Start incision
10:50pm Surgery completed
11:45pm Rat movement; began recovery
from anesthesia
6:30am
Subcutaneous injection of 0.04cc
Buprenorphine
Unknown Rat dies a few days after surgery

7:27am
7:32am
7:45am
8:45am

10

10/5/2008

8:05am

11/15/2008

5:45pm

10/4/2008

Sponge on top
with rhBMP-2

7:45am
7:52am

8:02am
8:05am
8:21am
9:30am

11

10/5/2008

8:08am

11/15/2008

5:50pm

10/4/2008

Sponge on top
with rhBMP-2

8:19am
8:28am

36

IP injection of 0.19cc Ketamine
and 0.22cc Xylazine
Subcutaneous injection of 0.044cc
Buprenorphine and 15cc saline
Apply 0.09cc reconstituted BMP-2
on collagen sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.044cc
Buprenorphine
Euthanized by CO2 asphyxiation
Apply 0.09cc reconstituted BMP-2
on collagen sponge
IP injection of 0.20cc Ketamine
and 0.23cc Xylazine
Subcutaneous injection of 0.046cc
Buprenorphine and 15cc saline
Start incision
Additional IP injection of 0.10cc
Ketamine and 0.10cc Xylazine
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.044cc
Buprenorphine
Euthanized by CO2 asphyxiation
Apply 0.09cc reconstituted BMP-2
on collagen sponge
IP injection of 0.18cc Ketamine
and 0.20cc Xylazine
Subcutaneous injection of 0.041cc

Rat #

Date

Sponge Type

Time
8:36am
8:37am
9:00am
10:00am

19

10/5/2008

8:10am

11/15/2008

5:50pm

10/4/2008

Sponge on top
with rhBMP-2

9:33pm

Control, sponge
on top

9:08am

10/8/2008
21

10/5/2008

Apply 0.09cc reconstituted BMP-2
on collagen sponge
9:48pm
IP injection of 0.20cc Ketamine
and 0.23cc Xylazine
Subcutaneous injection of
0.0454cc Buprenorphine and 15cc
saline
10:04pm Start incision
10:22pm Surgery completed
Unknown Rat dies a few days after surgery

9:30am
9:32am
9:50am
11:10am

22

10/6/2008

8:08am

11/15/2008

6:30pm

10/5/2008

Sponge on top
with rhBMP-2

Action
Buprenorphine and 15cc saline
Start incision
Additional IP injection of 0.10cc
Ketamine and 0.10cc Xylazine
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.044cc
Buprenorphine
Euthanized by CO2 asphyxiation

9:40am

9:41am

37

IP injection of 0.16cc Ketamine
and 0.19cc Xylazine
Subcutaneous injection of
0.0371cc Buprenorphine and 15cc
saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0371cc Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.20cc Ketamine
and 0.22cc Xylazine
Subcutaneous injection of
0.0446cc Buprenorphine and 15cc
saline
Apply 0.09cc reconstituted BMP-2
on collagen sponge

Rat #

23

Date

Sponge Type

Time
9:58am
10:18am
11:45am

10/6/2008

8:10am

11/15/2008

6:35pm

10/5/2008

Sponge on top
with rhBMP-2

10:10am

10:44am
10:45am
10:18am
11:11am
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10/6/2008

8:15am

11/15/2008

6:35pm

2/7/2009

Control, sponge
on top

3:30pm

3:40pm
3:45pm
4:10pm
5:00pm

26

2/8/2009

8:20am

3/21/2009

2:30pm

2/7/2009

Sponge on top
with rhBMP-2

4:55pm

5:10pm
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Action
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0446cc Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.16cc Ketamine
and 0.18cc Xylazine
Subcutaneous injection of
0.0364cc Buprenorphine and 15cc
saline
Apply 0.09cc reconstituted BMP-2
on collagen sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0364cc Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.22cc Ketamine
and 0.22cc Xylazine
Subcutaneous injection of
0.0446cc Buprenorphine and 15cc
saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0446cc Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.25cc Ketamine
and 0.24cc Xylazine
Subcutaneous injection of
0.0465cc Buprenorphine and 15cc
saline
Apply 0.09cc reconstituted BMP-2
on collagen sponge

Rat #

Date

Sponge Type

Time
4:15pm
4:10pm
5:20pm

Sponge on top
with rhBMP-2

9:50pm

2/8/2009
27

2/7/2009

Action
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Unknown Rat dies a day after surgery

9:57pm
10:10pm
10:50pm
12:30am
2/8/2009

8:30am

3/21/2009

2:30pm
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IP injection of 0.25cc Ketamine
and 0.24cc Xylazine
Subcutaneous injection of
0.0465cc Buprenorphine and 15cc
saline
Apply 0.09cc reconstituted BMP-2
on collagen sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0465cc Buprenorphine
Euthanized by CO2 asphyxiation

Appendix B
Preliminary Experiment Using One Rat
One rat was used to determine the following:
1. Effectiveness of anesthesia
A mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine,
10 mg/kg body weight of Xylazine) should be used for inducing general
anesthesia. The source used to determine these dosages is Lumb and Jones
Veterinary Anesthesia and Analgesia, 4th Ed. by W. J. Tranquilla. In addition, a
dose of Buprenorphine should be administered subcutaneously (0.01-0.05 mg/kg)
between the shoulder blades to mitigate pain [24]. The Ketamine/Xylazine
mixture provides approximately 30 minutes of effective anesthesia, and a ½ dose
must be available to continue the anesthesia if the surgery takes longer than
expected. The Ketamine/Xylazine and Buprenorphine mixture works well
because emergence from anesthesia is smoother and it has a high factor of safety.
The reason why the Ketamine/Xylazine and Buprenorphine mixture is chosen
over an inhalant anesthetic, such as Halothane, is because Halothane requires that
the rats wear a mask during surgery. Unfortunately, this mask would interfere
with the surgical site, and therefore the Ketamine/Xylazine and Buprenorphine
mixture is the better choice.

2. Instrumentation needed
Tray for BMP-2 procedures, BMP-2 / ACS (already prepared with center
hole on ACS and sterilized), syringes, forceps, fine forceps, ultrafine forceps,
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weight boat, bench covers, sterile gowns, scrubs, mask, rat gloves, nitrile gloves,
sterile gloves, Ketamine, Xylazine, Buprenorphine, shaver, depilatory cream
(Veet®), Betadine solution, Petri dish with saline, surgical drapes, scissors,
scalpel, butyl cyanoacrylate / applicator, glass slab for butyl, head cap, cotton
gauze and swabs (both sterile and non-sterile), disposable bag for blood and
contaminated items, heating pad, recovery bin, etc.

3. Preparation / Surgical procedures
A clean, uncluttered, and sanitized work surface should be used for prep
and surgery. Aseptic procedures must be followed:

Pre-operative:
a. Sterilize instruments (using the method of heat sterilization) needed for
prep and surgery: tray for rhBMP-2 procedures, forceps, fine forceps,
ultrafine forceps, scissors, scalpel, butyl cyanoacrylate applicator, glass
slab for butyl, surgical drapes, syringes, gloves, Petri dish with saline,
cotton gauze, and cotton swabs.
b. Bring to surgical suite: sterile instruments mentioned above as well as
butyl cyanoacrylate, tupperware for weighing the rat, isolation mask and
cap, sterile gowns, bench covers, weight boat, and rat in the cage.
c. Obtain in surgical suite: Ketamine, Xylazine, Buprenorphine, scrubs, rat
gloves, nitrile gloves, sterile gloves, shaver, depilatory cream (Veet®),
Betadine solution, disposable bag for blood and contaminated items,
heating pad, recovery bin, and non-sterile cotton swabs and gauze.
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d. In an area of the surgical suite, separate from the prep and surgery area, an
assistant must wash their hands, put on sterile gloves, and do the
following: 1) take a 1 cm x 1 cm absorbable collagen sponge with sterile
forceps and wet it with 0.09 cc of saline (for a control TAD) or 0.09cc of
reconstituted rhBMP-2 (for an rhBMP-2 treated TAD) using a syringe and
a sterile tray, and 2) let it stand for at least 15 minutes before use.
Meanwhile, continue with the following pre-operative procedures.
e. Weigh the animal in a weight boat to determine the appropriate dosages of
Ketamine, Xylazine, and Buprenorphine. The amount of anesthesia given
to a rat is determined by the following criteria: 44 mg/kg body weight of
Ketamine, 10 mg/kg body weight of Xylazine, and 0.01 – 0.05 mg/kg
body weight of Buprenorphine. Record the dosages in the lab notebook.
f. Place a bench cover down on the table.
g. Put on rat gloves and grab the animal around the torso to administer the
anesthesia. Use a mixture of Ketamine and Xylazine (44 mg/kg body
weight of Ketamine, 10 mg/kg body weight of Xylazine) for inducing
general anesthesia. This will provide approximately 30 minutes of
effective anesthesia.
h. In addition, administer a dose of Buprenorphine subcutaneously (0.01 –
0.05 mg/kg body weight) between the shoulder blades. The
Ketamine/Xylazine and Buprenorphine mixture works well because
emergence from anesthesia is smoother and has a high factor of safety.
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Place the rat in a chamber until the anesthesia takes effect and the animal
is down.
i. Throw out the bench cover and place a new one for prepping. An assistant
will start the prepping of the animal while the individual performing the
surgery starts the surgical scrub and puts on a sterile gown to prepare for
surgery.
j. Assistant: put scrubs and nitrile gloves on for prepping procedures.
k. Take the rat out of the chamber and place on the bench cover. Use the
clippers provided in the surgical suite to shave the surgical site (rat’s
head). Then, apply depilatory cream on the surgical site. Wait a few
minutes for the depilatory cream to set. Rub the surgical site with a damp
2 x 2 cotton sponge to remove excess hair.
l. Pour Betadine antiseptic solution on a swab and apply it to the rat’s head
in a circular motion. Repeat a minimum of 3 times. Put the animal back
in the chamber.
m. Throw away the bench cover.
n. Disinfect the table to maintain a clean, uncluttered, and sanitized area.
Use gauze sponge to wipe it down.
o. Place down a new bench cover.
p. Put the rat down on the new bench cover.
q. Take off nitrile gloves and wash hands.
r. Take pre-sterile surgical packages with surgical drape and sterile
instruments, sterile gloves, isolation mask and cap, butyl
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cyanoacrylate/applicator, glass slab, gauze, and cotton swabs and place
them on the table within reach of the individual performing surgery.
s. Put the heating pad in the microwave so it is ready to heat up once surgical
procedures are completed.
t. Open up the sterile surgical package cover, and open up covering for
sterile instruments (without touching the actual instruments).
u. Once the “surgeon” has scrubbed and put on the sterile gown, he/she must
put on the sterile gloves and sit down to begin surgery.
v. The surgeon should now pull out the surgical drape from the sterile
surgical packages and place it on the animal. Use forceps and scissors to
cut drape at incision site. Use other forceps and scissors to do actual
incision (internal work).

Operative:
a. Begin surgery with sterile instruments and handle instruments aseptically.
b. Using the “tips-only” technique, make an incision along the line from the
middle of the eyes to the middle of the ears.
c. Once the incision is made, carefully fold back the periosteum using sterile
instruments (i.e. scalpel, forceps, etc.).
d. When the bony complex on the surface of the cranium is exposed, use
sterile forceps to pick up a titanium implant, contour it to fit the skull
shape, and place it on the bony complex. With the help of an assistant,
glue the implant to the bone with butyl cyanoacrylate. Wait
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approximately 2 minutes to set. Use a sterile instrument to place the
collagen sponge on top of the implant. The collagen sponge will be soaked
in saline or rhBMP-2 depending on whether it is a control implant or not.
e. While surgery is in progress, continually monitor the animal’s vital signs.
f. Once the implant is stable, place as much of the periosteum over the
implant.
g. Use sterile forceps to hold the sides of skin at the incision site together
while an assistant closes the incision site using butyl cyanoacrylate. At
this point, have another assistant go to the microwave to heat up the
circulating heating pad for about 3-4 minutes to heat up to 37 degrees.

Post-Operative:
a. Remove the surgical drape.
b. Give the rat a subcutaneous injection of Buprenorphine (0.01 - 0.05
mg/kg).
c. Move the rat to a warm area (recovery bin) to return its body temperature
back to normal. In the recovery bin, place the rat on a blue bench cover,
above a heating pad, to allow it to recover. Return the animal to its
routine housing only after full recovery from anesthesia. Each rat will be
caged separately.
d. Buprenorphine (0.01 -0.05 mg/kg) should be administered 3 times a day
for 2 days as necessary for pain management. In the event of an infection,
the wound site will be cleaned 2 times/day with Betadine solution.
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e. The rats will be visually inspected daily post-op for infection. A surgical
record (procedure, date, anesthesia dose, route of administration) will be
maintained.

4. Surgical site to least elicit blood flow, angulations, and location of incision
The incision should be made in such a way that it elicits the least amount
of blood flow. In terms of the vascular structures in a rat, the common carotid
artery splits into the internal and external carotid arteries ventral to the auditory
bulla (bony capsule enclosing the middle and inner ear). The internal carotid
artery moves anteriorly to supply blood to the brain and the external carotid artery
moves anteriorly to supply blood to most of the structures of the head. To avoid
compromising the rat’s vascular system, an incision approximately 1 inch in
length should be made along the midline of the skull. The midline incision in the
scalp should be made using firm pressure to guarantee a clean cut in a single
stroke. The incision should be made from the area between the eyes to the area
between the ears. Then, once the incision is made, the periosteum can be carefully
removed. The periosteum can be pulled back and removed from the skull using
scalpel, forceps and scissors.

5. Implant contour, adhesion method, and incision site closure
The site(s) should be chosen such that the TAD follows the contour of the
skull in the best way possible. The TAD should be placed on the cranial bone
such that its distance from the cranial surface is as close as possible. Only one
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implant can be successfully placed on the skull and covered with the periosteum.
The periosteum is too thin and does not sufficiently cover two implants at one
time. Therefore, only one implant will be used for each rat. Butyl cyanoacrylate
will be used to ensure the adhesion of the implant to the bone and for closure of
the incision.

6. Implant size and protruding length
One 7 mm diameter TAD can fit on one rat skull. A protruding length of
2 mm on one side is sufficient enough for biomechanical testing and small enough
to prevent the rat from knocking it off. The surgical procedures should be purely
subcutaneous so that the protruding part of the implant will be under the skin.
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Appendix C
Surgery Checklist
Date____________

Rat Skull Surgery

Rat Information
Breed: _______________
Sex: ________________
Weight: ______________
Tag: _________________
Cage: ________________
Materials
Sterilized Instruments
___1. forceps
___2. fine forceps
___3. ultrafine forceps
___4. scissors
___5. scalpel
___6. cotton gauze
___7. cotton swabs
Bring to Surgical Suite
___8. sterile surgical drapes
___9. sterile syringes
___10. butyl cyanoacrylate/applicator/glass slab
___11. sterile gown, mask and cap
___12. bench covers
___13. weight boat
Obtained in Surgical Suite
___14. anesthesia (Ketamine and Xylazine)
___15. analgesic (Buprenorphine)
___16. scrubs
___17. rat gloves
___18. sterile gloves
___19. shaver
___20. depilatory cream (Veet®)
___21. Betadine solution
___22. disposable bag for blood and contaminated items
___23. heating pad
___24. recovery bin
___25. non-sterile cotton swabs
___26. non-sterile cotton gauze
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Initials____________

rhBMP-2/ACS Preparation or Saline/ACS Preparation
___27. Take a 1 cm x 1 cm absorbable collagen sponge and wet it with 0.09cc of saline
(for a control TAD) or 0.09 cc of
reconstituted rhBMP-2.
___28. Let collagen sponge stand for at least 15 minutes before use.
Surgery Preparation
___29. Weigh animal in weight boat.
___30. Put on rat gloves and grab animal around torso to administer anesthesia. Use a
mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine, 10
mg/kg body weight of Xylazine). Record dosages in the lab notebook.
___31. Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg
body weight). Record dosage in the lab notebook.
___32. Place rat in chamber (anesthesia box) to let the anesthesia take effect.
___33. Surgeon: put on mask/cap, perform surgical scrub, and put on sterile gown and
gloves to prepare for surgery.
___34. Assistant: put scrubs and nitrile gloves on. Perform prepping procedures below.
___35. Place bench cover on table for preparation procedures.
___36. Take rat out of chamber and place on bench cover.
___37. Shave hair on surgical site (rat’s head) using clippers.
___38. Apply depilatory cream to surgical site and wait a few minutes.
___39. Rub surgical site with a damp 2 x 2 cotton sponge to remove excess hair.
___40. Apply Betadine solution on the rat’s head a minimum of 3 times in a circular
motion.
___41. Return rat to chamber.
___42. Throw away bench cover.
___43. Disinfect table. Use gauze to wipe it down.
___44. Place down a new bench cover.
___45. Put the rat down on the new bench cover.
___46. Take off nitrile gloves and wash hands.
___47. Place pre-sterile surgical packages (with sterile drape), sterile instruments, sterile
gloves, and isolation mask and cap on the table.
___48. Place heating pad in microwave so it is ready to heat up once surgery is done.
___49. Put on mask and cap.
___50. Open up sterile surgical packages (sterile drape and instruments) without
touching the inside of the sterile packages.
Surgery
___51. Surgeon: pull out sterile surgical drape from sterile package and put over rat.
Perform surgery procedures below.
___52. Use forceps and scissors to cut drape at incision site.
___53. Make an incision along the midline of the rat’s head, from the middle of the eyes
to the middle of the ears.
___54. Carefully fold back the periosteum using forceps.
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___55. Use sterile forceps to pick up a titanium implant and contour it to fit the shape of
the skull.
___56. Place implant on bony complex.
___57. With the help of an assistant, glue implant to bone with butyl cyanoacrylate.
Let it set for about 2 minutes.
___58. Use a sterile instrument to place the collagen sponge/rhBMP-2 or collagen
sponge/saline on top of the implant.
___59. Close the incision using butyl cyanoacrylate. At this time, have an assistant
microwave the heating pad for about 45 seconds.
Post-Surgical
___60. Remove surgical drape.
___61. Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg).
___62. Place rat in recovery bin, on a blue bench cover, above a heating pad to allow to
recover.
___63. Return rat to its routine housing only after full recovery from anesthesia. Each
rat will be caged separately.

50

Appendix D
Preliminary Experiment Using INFUSE® Bone Graft Sample Kit
Note: A buffer was used to substitute for the rhBMP-2 in the sample kit
Questions to be answered from the experiment:
•

Is it possible or necessary to separate the rhBMP-2 and sterile water into separate
vials for smaller samples? If so, how should this be done?

•

Is the effectiveness of the rhBMP-2 / sterile water mixture compromised if it is
not used all at one time?

•

What tools are necessary to cut the absorbable collagen sponge (ACS) into its
desired shape?

•

Should the collagen sponge be cut before or after the rhBMP-2 / sterile water
mixture is applied to it?

•

How much ACS is need for one implant?

•

4.0 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen sponges.
How much of the reconstituted rhBMP-2 is needed for just 1 collagen sponge? ½
of a collagen sponge? Etc.?

•

How can a hole be created in the middle of the shaped sponge for the protruding
part of the implant?

•

Since the kit states that the wet collagen sponges must be used within 2 hours,
how many rats can undergo surgery within 2 hours with the assumption that the
sponges will be prepared before the surgeries begin?

Experimental procedure
•

Take a 10 mL syringe out into the field, and draw 8.4 mL of sterile water into the
syringe.

•

Inject 8.4 mL of sterile water into the buffer powder vial and swirl the vial to
ensure adequate mixing.

•

Open the collagen sponge package and take out one of the collagen sponges.
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•

Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen
sponges, calculate the amount of mixture needed for 1 collagen sponge: 4 mL / 3
sponges = 1.33 mL / sponge.

•

Use another 10 mL syringe to withdraw 1.33 mL of reconstituted rhBMP-2 from
the vial.

•

Uniformly distribute 1.33 mL of reconstituted rhBMP-2 on 1 of the 2.5 cm x 5 cm
collagen sponges.

•

Allow the wet collagen sponge to stand for 15 minutes.

•

After 15 minutes, use 2 different tools to cut the collagen sponge in the shape of
the implant.

•

Place a sample implant on the collagen sponge and used an x-acto knife to cut
around the outer edge of the implant.

•

Using another section of the collagen sponge, use a 1-hole punch to punch a hole
through the wet sponge.

•

Take out a second collagen sponge. This time, cut the non-wetted sponge with the
x-acto knife. Likewise, use the 1-hole punch on the non-wetted sponge.

Results and Conclusions of Preliminary Experiment
•

It is not necessary to separate the rhBMP-2 and sterile water into smaller vials.
As long as the reconstituted rhBMP-2 is refrigerated, it can be used at another
point in time. The effectiveness of the rhBMP-2 / sterile water mixture is not
compromised if it is not used all at once. The kit instructions state that the wet
collagen sponge must be used within 2 hours, but there is nothing stating that the
rhBMP-2 / sterile water mixture must be used within 2 hours.

•

The 1-hole punch is not a good tool for the purposes of this study because it
punches out a diameter that is smaller than the diameter of the implant for both
the non-wetted and wet sponge.

•

It is difficult to cut a circular shape with the x-acto knife on a wet sponge.
However, the x-acto knife works better when making straight cuts on the wet
sponge.
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•

It is difficult to cut a circular shape through a non-wetted sponge with the x-acto
knife, but easy to cut straight lines.

•

Cutting the non-wetted sponge is easier than cutting the wet sponge.

•

A 1.00 cm x 1.25 cm section (1/10 of 1 collagen sponge) of a non-wetted sponge
is needed for 1 implant. Once the sponge is wet, it can be shaped circularly to
follow the shape of the implant.

•

The successful way of applying the collagen sponge to the implant:
1. Cut one non-wetted collagen sponge (2.5 cm x 5 cm) into 10 equal
sections (1.00 cm x 1.25 cm).

Figure D-1 – Collagen Sponge Dimensions
Note: Figure not drawn to scale
2. Use a plastic head pushpin to create a hole in the center of one 1.00 cm x
1.25 cm piece for the protruding part of the implant.
3. Apply the rhBMP-2 / sterile water mixture to that same 1.00 cm x 1.25 cm
section. Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3
collagen sponges, the amount of mixture needed for 1 collagen sponge is 4
mL / 3 sponges = 1.33 mL / sponge. However, since one collagen sponge
is divided into 10 equal sections, 1/10 * 4/3 = 0.133 mL of the rhBMP-2 /
sterile water mixture is needed per section. The syringe given in the kit is
a 10 mL syringe with increments of 0.2 mL. For better accuracy, use a
smaller syringe with smaller increments.
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4. After waiting at least 15 minutes, place the wet collagen sponge over the
implant and shape the collagen sponge into a circular form (which follows
the shape of the implant).
•

Since the wet collagen sponge must be used within 2 hours, only wet a 1.00 cm x
1.25 cm section of absorbable collagen sponge before each rat goes through
surgery.

•

Note: the collagen sponge pieces used during the actual surgery were different in
size than those used during the experimental phase. Specifically, 1 cm x 1 cm
pieces were used with 0.09 cc of reconstituted rhBMP-2.
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Appendix E
Anesthetics/Analgesics
Bottle Concentrations (mg/mL)
Ketamine HCl: 100 mg/mL
Xylazine: 20 mg/mL
Buprenorphine HCl: 0.3 mg/mL

Dosage (mg/kg of body weight)
Ketamine HCl: 44 mg/kg
Xylazine: 10 mg/kg
Buprenorphine HCl: 0.03 mg/kg

Table E-1 - Number of mL Administered of Each Drug Based on Weight
Weight of Rat (g)
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310

Weight of Rat (kg)
0.200
0.205
0.210
0.215
0.220
0.225
0.230
0.235
0.240
0.245
0.250
0.255
0.260
0.265
0.270
0.275
0.280
0.285
0.290
0.295
0.300
0.305
0.310

Ketamine (mL)
0.088
0.090
0.092
0.095
0.097
0.099
0.101
0.103
0.106
0.108
0.110
0.112
0.114
0.117
0.119
0.121
0.123
0.125
0.128
0.130
0.132
0.134
0.136
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Xylazine (mL)
0.100
0.103
0.105
0.108
0.110
0.113
0.115
0.118
0.120
0.123
0.125
0.128
0.130
0.133
0.135
0.138
0.140
0.143
0.145
0.148
0.150
0.153
0.155

Buprenorphine (mL)
0.020
0.021
0.021
0.022
0.022
0.023
0.023
0.024
0.024
0.025
0.025
0.026
0.026
0.027
0.027
0.028
0.028
0.029
0.029
0.030
0.030
0.031
0.031

315
320
325
330
335
340

0.315
0.320
0.325
0.330
0.335
0.340

0.139
0.141
0.143
0.145
0.147
0.150
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0.158
0.160
0.163
0.165
0.168
0.170

0.032
0.032
0.033
0.033
0.034
0.034

Appendix F
Butyl Cyanoacrylate and the Effect of UV Light on Curing Time
In the presence of moisture, cyanoacrylates rapidly polymerize and set quickly. A
quick and easy way to test whether a certain type of cyanoacrylate will adhere to tissue
with degrees of moisture is to apply the cyanoacrylate to designated sections of the
implant and see if it adheres to cow bone or fresh meat from the grocery store. The tissue
found in cow bone is similar to the tissue found in rats, and therefore using the cow bone
allows for quick and effective testing without having to perform surgery on the rat for
this preliminary step. In addition, saliva added to the site of the implant accounts for the
presence of blood during the actual surgery. This aids in determining whether the saliva,
with chemical and physical components somewhat similar to blood, will have any effect
on the implant’s ability to adhere. From this experiment, the curing time and whether the
cyanoacrylate is an effective adhesive can be determined. Moreover, the effect of UV
light (which has been known to reduce curing time) will also be evaluated. Finding a way
to reduce the curing time is desired to ensure implant stability and to minimize the
amount of blood flow and other fluids into the implant site.

An experiment using Vetbond butyl cyanoacrylate was performed. The results
from the experiment can be found in the following table:
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Table F-1 – Vetbond Butyl Cyanoacrylate Curing Time
All trials used saliva to account for the presence of blood

Cow
Bone
New
York
Steak
Bone In
(Shaved
Bone)

Curing Time
Without UV
Light
(Trial 1)

Curing Time
Without UV
Light
(Trial 2)

2 minutes

2 minutes

1 minute, 50
seconds

1 minute, 55
seconds

2 minutes

2 minutes

1 minute, 50
seconds

2 minutes

Curing Time Curing Time
With UV
With UV
Light
Light
(Trial 1)
(Trial 2)

The curing time was determined based on the following graphs:

120
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80
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60
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120
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% Adhesion Strength vs. Curing Time
(cow bone, no UV light)

Curing Time (sec)

Figure F-1 – Curing Time Using Cow Bone without UV Light
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Figure F-2 – Curing Time Using NY Steak without UV Light
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Figure F-3 – Curing Time Using Cow Bone with UV Light
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Figure F-4 – Curing Time Using NY Steak with UV Light

Several conclusions were made from the above experiment:
•

Butyl cyanoacrylate is an effective adhesive.

•

Saliva does not affect the ability of the implant to adhere to bone. Thus, blood,
with chemical and physical components somewhat similar to blood, is also
assumed to have little effect on the ability of the implant to adhere to bone.

•

The curing time with UV light is less than the curing time without UV light.
However, the difference is not that significant.
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Appendix G
Bone Coverage Raw Data
Table G-1 – Photographs of TAD Bone Coverage for Each Rat
Bone Coverage
Rat #
Control or rhBMP-2 treated
(Photo taken prior to biomechanical
testing)

Rat 5

Control, sponge on top

Rat 6

Control, sponge on top

Rat 7

Control, sponge on top

Rat 9

Sponge on top w/ rhBMP-2

Rat 10

Sponge on top w/ rhBMP-2
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No bone coverage observed – TAD
migrated
N/A - rat died after surgery

Rat 11

Sponge on top w/ rhBMP-2

Rat 19

Sponge on top w/ rhBMP-2

Rat 21

Control, sponge on top

Rat 22

Sponge on top w/ rhBMP-2

Rat 23

Sponge on top w/ rhBMP-2
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N/A– rat died a few days after surgery

Rat 24

Control, sponge on top

Rat 26

Sponge on top w/ rhBMP-2

Rat 27

Sponge on top w/ rhBMP-2
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N/A - Rat died one day after surgery

Appendix H
Biomechanical Testing Failure Load Graphs

Note: No graphs are available for Rats 5, 6, 7, 19, 26. See explanation in the Results
Summary table in Section 4.2.1.

Rat 9
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Figure H-1: Failure Load for Rat #9

Rat 10
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0.8
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0.4
0.2
0
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Figure H-2: Failure Load for Rat #10

Rat 11
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Figure H-3: Failure Load for Rat #11

Rat 21
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Figure H-4: Failure Load for Rat #21
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Rat 22
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Figure H-5: Failure Load for Rat #22

Rat 23
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Figure H-6: Failure Load for Rat #23
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Rat 24
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Figure H-7: Failure Load for Rat #24

Rat 27
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Figure H-8: Failure Load for Rat #27
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